May 19, 2017, NIH Record, Vol. LXIX, No. 10

Total Page:16

File Type:pdf, Size:1020Kb

May 19, 2017, NIH Record, Vol. LXIX, No. 10 May 19, 2017 Vol. LXIX, No. 10 Surveys estimate that anywhere from 25 percent to 50 percent of all meetings are unproductive, Pittampalli said. People report BLOCK THE ‘PASSENGER’ they feel that as much as half the time they spend in meetings is wasted. By a show of Beware the Intruder Hijacking hands, NIH audience members nearly unan- Your Meetings imously confirmed—perhaps humorously, BY CARLA GARNETT perhaps not so much—that they’d attended at least one meeting that had made them Ever wonder why so many meetings are so reconsider their life’s purpose. unproductive? Chances are good an unin- “Nothing can ever take the place of vited guest has been riding shotgun. Turns human beings getting in a room together out this unseen hitchhiker loves to sabotage to talk things out,” Pittampalli acknowl- your well-organized, well-intentioned edged. “Meetings are at the heart of how we workplace gatherings. communicate, how we collaborate, how we At a recent Deputy Director for decide on the most important issues facing Management seminar, author and business the organization. If that’s weak, then it’s hard advisor Al Pittampalli, who has studied to fulfill the mission of the organization. I’m meetings for the past decade, introduced here to tell you the meeting is weak.” a Masur Auditorium audience to this Pittampalli was an IT consultant for invisible, yet powerful saboteur he calls Fortune 500 companies around the country Al Pittampalli addresses NIH audience. “the passenger.” SEE PITTAMPALLI, PAGE 6 Buck’s Research Helps Wagers Tracks Aging in Unravel Mysteries of Scent Muscle Cells BY ERIC BOCK You don’t need to be a gym rat to know that muscle matters; without it, we wither toward The sense of smell is extremely important our own personal finish line. in everyday life. It can, for example, warn “Declining muscle function is a significant us of danger contributor to deficiencies in health and or alert us to a powerful predictor of mortality,” said the presence of Dr. Amy Wagers, who studies how tissues food. Thanks to maintain them- “Cell-fies” at Science Day. See story, p. 9 researchers like selves and how Dr. Linda Buck, ALSO THIS ISSUE they regenerate scientists can over time. Briefs ....................................2 now better learn Wagers is Cystic Echinococcosis Is Focus of 2017 Neva how smell works. Forst family Memorial Lecture ..........................3 “Through the professor of stem sense of smell, Dr. Linda Buck NIH, Indian Council of Medical Research cell and regen- humans and Staff Meet ................................5 erative biology other mammals can detect a vast array of at Harvard The Art of Sealing the Biomedical Tech Deal ..7 chemicals in the environment,” said Buck, University and Science Day Seeks to Empower Students ....9 Nobel laureate (2004) and full member of Harvard Medical the basic sciences division at Seattle’s Fred Milestones ...............................10 School, senior Hutchinson Cancer Research Center, at the investigator, Seen ....................................12 SEE BUCK, PAGE 8 Dr. Amy Wagers SEE WAGERS, PAGE 4 BRIEFS Essence Editor Emeritus Taylor To Speak, May 22 in Lipsett The Office of Equity, Diversity and Inclusion will host Susan L. Taylor, editor-in-chief emeritus of Essence magazine in a lecture at NIH on Monday, May 22 at 11 a.m. in Lipsett Amphitheater, Bldg. 10. The talk celebrates Women in History with the theme “Be Inspired” in honor of NIH’s commitment to EDI 365 and in support of equal opportunities for women to achieve their fullest potential. When Taylor joined Essence in 1970, she was the only single mom on staff. As she moved up the editorial ladder, she NIGMS Lecturer Describes Her Research, Career Path stressed the Dr. Namandjé Bumpus (l) recently delivered the second annual NIGMS Director’s Early Career importance of Investigator Lecture. In her talk “Drug Metabolism, Pharmacogenetics and the Quest to Personalize enabling female HIV Treatment and Prevention,” Bumpus described her research investigating the mechanisms involved Susan L. Taylor staffers to live in HIV drug activation and metabolism. She then engaged in an informal Q&A session with NIGMS their personal director Dr. Jon Lorsch (r) as well as answered questions from students. Bumpus discussed her career lives as fully as path, including when she knew she wanted to be a scientist, what she would have done differently and how mentors have supported her. After the talk, Bumpus met with University of Maryland their professional lives. Serving as editor-in-chief undergraduates (from l) Natalia Fongrat, Jayshree Surage and Dorcas Adeola. Bumpus is an associate for 19 years, she helped Essence expand beyond professor in the department of medicine, division of clinical pharmacology at Johns Hopkins University publication with branded products and events School of Medicine. The lecture is archived on the NIH VideoCasting and podcasting site. such as the Women Who Are Shaping the World PHOTO: CHRISTA REYNOLDS Leadership Summit. Taylor is the first and only African-American woman recognized by the Magazine Publishers of America, winning the industry’s highest honor— the Henry Johnson Fisher Award. She was also inducted into the American Society of Magazine Editors Hall of Fame. In addition to being a gifted writer, speaker and entrepreneur, Taylor is founder and CEO of the National CARES Mentoring Movement, which focuses on emotional, social and academic development. The lecture will be available to view live at video- cast.nih.gov. Individuals with disabilities who need sign language interpreters and/or reasonable accommodation to participate in this event should contact Joy Gaines at (301) 451-9662 or [email protected]. Your Science on Our Masthead CC Celebrates Medical Laboratory Professionals The masthead atop each new issue of the NIH Members of the Clinical Center’s department of laboratory medicine celebrated Medical Laboratory Record relies on color scientific images submitted Professionals Week on Apr. 26. Special guest was hospital CEO Dr. James Gilman (suited at rear, l), who by NIH scientists or grantees. We need fresh enjoyed lunch with members of the department. Next to Gilman is department chief Dr. Thomas A. Fleisher. images for future issues of the Record. If your PHOTO: ERNIE BRANSON laboratory has a candidate image, email a high-res- olution color digital photo to the editors (Rich. [email protected], [email protected]), along with a brief caption and credit line. Since the space we need to fill is horizontal, images that work best in that orientation are most appreciated. 2 • NIH RECORD • MAY 19, 2017 costing devel- and wait.” The WHO working group on Cystic Echinococcosis Is oping echinococcosis advocates for improved Focus of 2017 Neva Memorial economies care and evidence-based treatment, hoping billions of to move echinococcosis into mainstream Lecture dollars every clinical medicine. year, according Junghanss reviews best practices for Dr. Thomas Junghanss, a tropical medicine to the WHO. diagnosing and treating CE and hopes to and infectious disease physician and chair Cystic echino- close knowledge gaps to provide better care of the World Health Organization working coccosis (CE), for patients suffering from one of the most group on echinococcosis, will present a parasitic neglected tropical diseases. the annual Franklin A. Neva Memorial NTD most The lecture series honors Neva, a noted Lecture on May 25 at 10 a.m. in Lipsett prevalent in Dr. Thomas Junghanss virologist, parasitologist, clinician and Amphitheater, Bldg. 10. His talk is titled sheep-raising former chief of the NIAID Laboratory of “Cystic Echinococcosis—Staging Matters.” regions of the Parasitic Diseases. He helped grow parasi- Cystic echinococcosis is a parasitic type of world, is caused by larval-stage tapeworms tology research at NIH from a narrow area of tapeworm infection. (Echinococcus granulosus) found in dogs, focus to a large program now spread among Junghanss heads the clinical tropical the primary host. Ungulates are inter- 4 NIAID research groups and involving medicine unit at Heidelberg University mediate hosts. Humans become infected about 400 scientific staff at laboratories in Hospital in Germany. He works in a broad accidentally by consuming food, water or Bethesda and abroad. Neva died in 2011 at range of settings at the hospital and in soil contaminated with infected dog feces. age 89. countries with limited resources. Disease is caused by cysts that grow In 2016, he received the Order of Merit slowly and quietly over many years, of the Federal Republic of Germany for mainly in the liver and lungs, but also in his contributions to tropical medicine in other organs. The cysts can cause dis- sub-Saharan Africa. comfort and symptoms or be detected by Junghanss was initially trained in marine chance. Treatment of advanced disease is geology with a focus on reef development, demanding: health services are regularly which gave him a deeper understanding of overextended in countries with limited ecology. His work has also been informed resources where most CE patients live. ON THE COVER: Adult Caenorhabditis elegans, 5 days old. C. elegans has become one of the most by his fascination with the philosophical Immigrants to non-endemic countries studied organisms on the planet. Researchers have undercurrents of the 20th century and the often face health care institutions unfamil- determined that C. elegans has exactly 959 cells, Anthropocene—the era of man’s influence on iar with CE. 302 of which are neurons. Earth ecology. CE imaging has been a breakthrough in IMAGE: COLLEEN MURPHY, PRINCETON UNIVERSITY He has a special interest in neglected helping to guide treatment decisions. Most tropical diseases (NTDs), which affect clinicians agree on four treatment options: The NIH Record more than 1 billion people in 149 countries, drugs, skin treatments, surgery and “watch Since 1949, the NIH Record has been published biweekly by the Editorial Operations Branch, Office of Communications and Public Liaison, June 6 National Institutes of Health, Department of Health and Human Services.
Recommended publications
  • Philip M. Cox January 27, 2017
    CURRICULUM VITAE Philip M. Cox January 27, 2017 Educational History: Ph.D. 2016 Program in Pharmacology Johns Hopkins University School of Medicine Mentor: Namandjé N. Bumpus, Ph.D. B.S. 2010 Biology-Chemistry Southern Nazarene University Professional Experience Assistant Professor 2017 - Azusa Pacific University, Azusa, CA Department of Biology and Chemistry Graduate Student 2012-2016 Lab of Namandje Bumpus, Ph.D. Johns Hopkins University School of Medicine, Baltimore, MD Research Technician 2010-2012 Lab of Darise Farris, Ph.D. Oklahoma Medical Research Foundation, OKC, OK Summer Student 2009 Lab of Kenneth Kaye, Ph.D. Harvard Medical School, Boston, MA Summer Student 2008 Lab of John Iandolo, Ph.D. University of Oklahoma Health Sciences Center, OKC, OK Summer Student 2007 Lab of Swapan Nath, Ph.D. Oklahoma Medical Research Foundation, OKC, OK External Funding: National Science Foundation Graduate Research Fellowship, September 2013-December 2016 Peer-Reviewed Publications: Cox PM, Bumpus NN. (2016) Single Heteroatom Substitutions in the Efavirenz Oxazinone Ring Impact Metabolism by CYP2B6. ChemMedChem. doi:10.1002/cmdc.201600519 Cox PM, Bumpus NN. (2014) Structure-Activity Studies Reveal the Oxazinone Ring Is a Determinant of Cytochrome P450 2B6 Activity Toward Efavirenz. ACS Med Chem Lett. 10:1156- 1161. PMCID: PMC4191608 Dumas EK, Nguyen ML, Cox PM, Rodgers H, Peterson JL, James JA, Farris AD. (2013) Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization. Vaccine. 14:1856-63. PMCID: PMC3614092 Garman L, Dumas EK, Kurella S, Hunt JJ, Crowe SR, Nguyen ML, Cox PM, James JA, Farris AD. (2012) MHC class II and non-MHC class II genes differentially influence humoral immunity to Bacillus anthracis lethal factor and protective antigen.
    [Show full text]
  • Investigating the Biological Role of O-Acyl ADP Ribose
    Investigating the Biological Role of O-Acyl ADP Ribose by Elyse Blazosky A thesis submitted to Johns Hopkins University in conformity with the requirements for the degree of Master of Science Baltimore, Maryland November, 2018 © Elyse Blazosky All Rights Reserved Abstract Sirtuins are an ancient family of deacetylase enzymes found in all three domains of life, where they have diverse biological roles. These widely studied enzymes are popular drug targets for treating diseases associated with aging, neurological disorders, cardiovascular disorders, metabolic disorders and even cancer. Unlike most deacetylase enzymes which use water to hydrolyze the amide bond linking the acetyl group to a lysine side chain, sirtuins catalyze a unique NAD+-dependent reaction that yields O-acetyl ADP ribose, nicotinamide and the deacetylate lysine. This seemingly wasteful use of NAD+ has led some to hypothesize that sirtuin activity is coupled to NAD+ levels in the cell. While sirtuin activity does rely on NAD+ biosynthesis and salvage pathways, it is unclear whether NAD+ levels fluctuate to a level that could affect sirtuin activity in-vivo. More recent studies have revealed new roles for sirtuins which suggests a more complex role of the sirtuin and a re-evaluation of the current hypothesis for why sirtuins uses NAD+. It has been shown that some sirtuins preferentially remove a variety of acyl lysine groups such as malonyl, succinyl, and butyryl, forming the corresponding O-acyl ADP ribose product. Mass spectrometry studies have revealed an abundance of these acyl modifications on cellular proteins, some of which are thought to result from non-enzymatic reaction with metabolites such as acyl-CoAs.
    [Show full text]
  • Efavirenz and Efavirenz-Like Compounds Activate Human, Murine, and Macaque Hepatic Ire1α-XBP1 Carley J.S
    Molecular Pharmacology Fast Forward. Published on November 15, 2018 as DOI: 10.1124/mol.118.113647 This article has not been copyedited and formatted. The final version may differ from this version. Efavirenz and Efavirenz-like Compounds Activate Human, Murine, and Macaque Hepatic IRE1α-XBP1 Carley J.S. Heck, Allyson N. Hamlin, and Namandjé N. Bumpus Department of Pharmacology & Molecular Sciences (C.J.S.H. and N.N.B.) and Department of Medicine – Division of Clinical Pharmacology (A.N.H and N.N.B.), Johns Hopkins University School of Medicine, Baltimore, MD, USA Downloaded from molpharm.aspetjournals.org at ASPET Journals on September 28, 2021 1 Molecular Pharmacology Fast Forward. Published on November 15, 2018 as DOI: 10.1124/mol.118.113647 This article has not been copyedited and formatted. The final version may differ from this version. Running title: EFV activates hepatic IRE1α-XBP1 Corresponding Author: Dr. Namandjé Bumpus, Department of Medicine, Division of Clinical Pharmacology, Johns Hopkins University School of Medicine, 725 N Wolfe Street, Biophysics Building 307A, Baltimore, MD 21205, USA Email: [email protected] Phone: 410-955-0562 Document statistics: Text Pages: 38 Tables: 0 Downloaded from Figures: 11 References: 52 Abstract: 245 words Introduction: 749 words Discussion: 1470 words molpharm.aspetjournals.org Abbreviations: 8-hydroxyefavirenz (8-OHEFV) Acridine Orange (AcrO) c-Jun N-terminal kinase (JNK) cytochrome P450 (CYP) at ASPET Journals on September 28, 2021 DNAJ heat shock protein family member 9 (DNAJB9) Efavirenz (EFV) Endoplasmic reticulum (ER) Ethidium Bromide (EtBr) Inositol requiring enzyme 1α (IRE1α) Pregnane X receptor (PXR) Reverse transcriptase- polymerase chain reaction (RT-PCR) Spliced XBP1 (sXBP1) Tunicamycin (TM) Unspliced XBP1 (uXBP1) X-box-binding protein 1 (XBP1) 2 Molecular Pharmacology Fast Forward.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,463,173 B2 Bumpus Et Al
    USOO94631 73B2 (12) United States Patent (10) Patent No.: US 9,463,173 B2 Bumpus et al. (45) Date of Patent: Oct. 11, 2016 (54) COMPOSITIONS AND METHODS FOR OTHER PUBLICATIONS TREATING OBESITY AND OBESTY-RELATED CONDITIONS Ghodke-Puranik, et. al., “Valproic acid pathway: pharmacokinetics and pharmacodynamics' Pharmacogenetics and genomics (2013). (71) Applicant: THE JOHNS HOPKINS Silva, M., et al., “Differential effect of valproate and its Delta2- and Delta4-unsaturated metabolites, on the beta-Oxidation rate of long UNIVERSITY, Baltimore, MD (US) chain and medium-chain fatty acids' Chem Biol Interact. (Sep. 28. 2001) vol. 137, No. 3, pp. 203-212. (72) Inventors: Namandje Bumpus, Washington, DC Zhang, L, et al., “Combined effects of a high-fat diet and chronic (US); Lindsay Avery, S. Hamilton, MA valproic acid treatment on hepatic Steatosis and hepatotoxicity in (US) rats'. Acta Pharmacol Sin. (Mar. 2014) vol. 35. No. 3, pp. 363-372. Meral, C., et al., “New adipocytokines (vaspin, apelin, visfatin, (73) Assignee: THE JOHNS HOPKINS adiponectin) levels in children treated with valproic acid” Eur UNIVERSITY, Baltimore, MD (US) Cytokine Netw. (Jun. 2011) vol. 22, No. 2, pp. 118-122. Acheampong, A., et al., “Identification of valproic acid metabolites *) Notice: Subject to anyy disclaimer, the term of this in human serum and urine using hexadeuterated valproic acid and patent is extended or adjusted under 35 gas chromatographic mass spectrometric analysis'. Biomed Mass U.S.C. 154(b) by 0 days. Spectrom (1983) vol. 10, No. 11, pp. 586-595. Becker, C., et al., “Influence of valproic acid on hepatic carbohy drate and lipid metabolism”, Arch Biochem Biophys (1983) vol.
    [Show full text]
  • Benzodiazepines Sixty Years Of
    A Publication by The American Society for the Pharmacology and Experimental Therapeutics Pharmacologist Vol. 61 • Number 1 • March 2019 INSIDE 2019 Election Results Sixty Years of 2019 Award Winners Benzodiazepines 2019 Annual Meeting Program The Pharmacologist is published and distributed by the American Society for Pharmacology and Experimental Therapeutics THE PHARMACOLOGIST PRODUCTION TEAM Rich Dodenhoff Catherine L. Fry, PhD Contents Tyler Lamb Judith A. Siuciak, PhD Suzie Thompson COUNCIL Message from the President 1 President Edward T. Morgan, PhD President Elect 2019 Election Results 3 Wayne L. Backes, PhD Past President John D. Schuetz, PhD 2019 Award Winners 4 Secretary/Treasurer Margaret E. Gnegy, PhD Secretary/Treasurer Elect 2019 Annual Meeting Program 11 Jin Zhang, PhD Past Secretary/Treasurer John J. Tesmer, PhD Feature Story – Councilors 26 Sixty Years of Benzodiazepines Carol L. Beck, PharmD, PhD Alan V. Smrcka, PhD Kathryn A. Cunningham, PhD Science Policy News Chair, Board of Publications Trustees 38 Mary E. Vore, PhD Chair, Program Committee Education News Michael W. Wood, PhD 42 FASEB Board Representative Brian M. Cox, PhD AMSPC News Executive Office 44 Judith A. Siuciak, PhD Journals News The Pharmacologist (ISSN 0031-7004) 45 is published quarterly in March, June, September, and December by the American Society for Pharmacology Membership News and Experimental Therapeutics, 1801 48 Rockville Pike, Suite 210, Rockville, MD Obituary: Brian Sorrentino 20852-1633. Annual subscription rates: $25.00 for ASPET members; $50.00 for U.S. nonmembers and institutions; Members in the News $75.00 for nonmembers and institutions 52 outside the U.S. Single copy: $25.00. Copyright © 2019 by the American Division News Society for Pharmacology and 54 Experimental Therapeutics Inc.
    [Show full text]
  • Semi-Solid Prodrug Nanoparticles for Long-Acting Delivery of Water-Soluble Antiretroviral Drugs Within Combination HIV Therapies
    ARTICLE https://doi.org/10.1038/s41467-019-09354-z OPEN Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies James J. Hobson1, Amer Al-khouja2, Paul Curley3, David Meyers2, Charles Flexner2,4, Marco Siccardi3, Andrew Owen 3, Caren Freel Meyers2 & Steve P. Rannard 1 fi 1234567890():,; The increasing global prevalence of human immunode ciency virus (HIV) is estimated at 36.7 million people currently infected. Lifelong antiretroviral (ARV) drug combination dosing allows management as a chronic condition by suppressing circulating viral load to allow for a near-normal life; however, the daily burden of oral administration may lead to non- adherence and drug resistance development. Long-acting (LA) depot injections of nanomilled poorly water-soluble ARVs have shown highly promising clinical results with drug exposure largely maintained over months after a single injection. ARV oral combinations rely on water- soluble backbone drugs which are not compatible with nanomilling. Here, we evaluate a unique prodrug/nanoparticle formation strategy to facilitate semi-solid prodrug nanoparticles (SSPNs) of the highly water-soluble nucleoside reverse transcriptase inhibitor (NRTI) emtricitabine (FTC), and injectable aqueous nanodispersions; in vitro to in vivo extrapolation (IVIVE) modelling predicts sustained prodrug release, with activation in relevant biological environments, representing a first step towards complete injectable LA regimens containing NRTIs. 1 Department of Chemistry, University of Liverpool,CrownStreet,LiverpoolL697ZD,UK.2 Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, 725 North Wolfe St., Baltimore, MD 21205, USA. 3 Department of Molecular and Clinical Pharmacology, University of Liverpool, Block H, 70 Pembroke Place, Liverpool L69 3GF, UK.
    [Show full text]
  • Divergence of Anti-Angiogenic Activity and Hepatotoxicity of Different Stereoisomers of Itraconazole
    Author Manuscript Published OnlineFirst on January 22, 2016; DOI: 10.1158/1078-0432.CCR-15-1888 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Divergence of Anti-angiogenic Activity and Hepatotoxicity of Different Stereoisomers of Itraconazole Joong Sup Shim1,2,3, Ruo-Jing Li1,3, Namandje N. Bumpus1,4, Sarah A. Head1, Kalyan Kumar1, Eun Ju Yang2, Junfang Lv2, Wei Shi1,5, Jun O. Liu1,6 1Department of Pharmacology and Molecular Sciences, 4Department of Medicine and 6Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA 2Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China 5Department of Chemistry and Biochemistry, University of Arkansas, Fayetteville, AR 72701, USA 3These authors contributed equally to this study. Correspondence to: Jun O. Liu, Ph.D, Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, 725 N Wolfe St, Hunterian Building 516, Baltimore, MD 21205 (e-mail: [email protected]) Running title: Distinct activity and toxicity of itraconazole stereoisomers Keywords: itraconazole, stereoisomers, drug repositioning, angiogenesis, hepatotoxicity Financial support: This work was supported in part by R01CA184103, the Flight Attendant Medical Research Institute (J. O. L.), the Johns Hopkins Institute for Clinical and Translational Research (ICTR) which is funded in part by Grant Number UL1 TR 001079 and the PhRMA foundation fellowship in Pharmacology/Toxicology (S. A. H.). Conflict of interest: Patents covering itraconazole and its stereoisomers as angiogenesis and hedgehog pathway inhibitors have been licensed from Johns Hopkins to Accelas Pharmaceuticals, of which J.O.L. is a cofounder and owns equity.
    [Show full text]
  • 40-Perkowski-Declaration-Iso-Pi
    Case 1:18-cv-01565-LMB-IDD Document 40 Filed 01/11/19 Page 1 of 8 Page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²VHUYLFHPHPEHUV YHWHUDQVFLYLOLDQ'HSDUWPHQWRI'HIHQVHDQGWKHLUVSRXVHVDQGIDPLOLHV²ZRUOGZLGH7KH RUJDQL]DWLRQ¶VPLVVLRQLVWRDGGUHVVDQGHQG²WKURXJKOLWLJDWLRQSROLF\DGYRFDF\DQG HGXFDWLRQ²DOOIRUPVRIXQHTXDORUXQIDLUWUHDWPHQWDJDLQVWPHPEHUVRILWVFRPPXQLW\EDVHGRQ VH[XDORULHQWDWLRQJHQGHULGHQWLW\RU+,9VWDWXV 2XW6HUYH6/'1LVLQSDUWDPHPEHUVKLSRUJDQL]DWLRQRUWKHIXQFWLRQDO HTXLYDOHQWRIDPHPEHUVKLSRUJDQL]DWLRQ,WKDVZHOORYHUPHPEHUV²YHWHUDQVDFWLYHGXW\ Case 1:18-cv-01565-LMB-IDD Document 40 Filed 01/11/19 Page 2 of 8 PageID# 221 DQGUHVHUYHFRPSRQHQWVHUYLFHPHPEHUVDQGFLYLOLDQ'HSDUWPHQWRI'HIHQVHZRUNHUV WKURXJKRXWWKHZRUOGZKRLGHQWLI\DV/*%74RUDUHOLYLQJZLWK+,9²DQGPRUHWKDQ VXSSRUWHUV2XW6HUYH6/'1DOVRKDVPRUHWKDQFKDSWHUVZRUOGZLGHLQFOXGLQJLQWKH 8QLWHG6WDWHVDQGDGGLWLRQDOVSHFLDOJURXSIRUXPVRQHRIZKLFKLVWKH³3RVLWLYH)RUXP´IRU SHRSOHOLYLQJZLWK+,97KHVHFKDSWHUVDUHQRWMXVWVRFLDOJURXSVEHFDXVHVHUYLFHPHPEHUVZKR DUH/*%74DQGRUOLYLQJZLWK+,9DUHPLQRULW\JURXSVWKDWDUHVWLOOVRPHWLPHVPDUJLQDOL]HG
    [Show full text]
  • ISSX President's Message
    Volume 40 Issue 4, 2017 ISSX President’s Message By Geoff Tucker, ISSX President The North American Meeting in or European regions were successful Finally, the time Providence, Rhode Island at the in the last round of elections. This for me to step end of September attracted 630 may reflect the current make-up of down as attendees, and Meeting Chairs ISSX membership, being 61% from President is Jash Unadkat and Alan Rettie are to North America and 19% from both approaching be congratulated on their excellent Asia Pacific and Europe, and is rapidly. In organization of a well-balanced clearly not sustainable for an Providence I program. For me, a highlight of international society. Accordingly, already passed the meeting was the outstanding Council agreed that the by-laws the chain of Geoff Tucker, Ph.D. presentations by the recipients should be modified to rectify the office (a rather ISSX President. of the North American Scientific situation. How exactly to assure attractive Achievement Awards, Kathy global representation is under accessory engraved with the names Giacomini and Namandje Bumpus. discussion and, in due course, of all previous Presidents that Steve members will be asked to ratify a Kemp keeps under lock and key) A face-to-face meeting of Council proposed change to the statutes. to my successor, Tom Baillie. in Providence allowed time for a Serving ISSX in the role of President reflective and productive discussion Meanwhile, programming plans for over the last two years has been on strategic issues, with focus the upcoming 2018 meetings in an interesting and enjoyable particularly on membership benefits, Montreal and China are proceeding experience.
    [Show full text]
  • Case 1:18-Cv-00641-LMB-IDD Document 26-5 Filed 07/19/18 Page 1 of 113 Pageid# 244
    Case 1:18-cv-00641-LMB-IDD Document 26-5 Filed 07/19/18 Page 1 of 113 PageID# 244 Exhibit E Case 1:18-cv-00641-LMB-IDD Document 26-5 Filed 07/19/18 Page 2 of 113 PageID# 245 UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF VIRGINIA Alexandria Division NICHOLAS HARRISON and OUTSERVE-SLDN, INC. Plaintiffs, v. Case No. 1:18-cv-641 (LMB/IDD) JAMES N. MATTIS, in his official capacity as Secretary of Defense; MARK ESPER, in his official capacity as the Secretary of the Army; and the UNITED STATES DEPARTMENT OF DEFENSE, Defendants. EXPERT DECLARATION OF CRAIG W. HENDRIX, M.D., IN SUPPORT OF PLAINTIFFS’ MOTION FOR PRELIMINARY INJUNCTION 1 Case 1:18-cv-00641-LMB-IDD Document 26-5 Filed 07/19/18 Page 3 of 113 PageID# 246 I. INTRODUCTION 1. My name is Craig W. Hendrix. I have been retained by counsel for Plaintiffs as an expert in connection with this litigation. 2. I am offering this declaration to provide my expert opinions regarding the U.S. Department of Defense and U.S. Army policies with respect to people living with HIV, including the purported medical justifications for preventing individuals living with HIV from joining the United States military, from being commissioned as officers, and—if already in the military— from deploying outside the United States. 3. As detailed below, it is my opinion that there are no medical justifications for excluding individuals from serving in any capacity in the military or from being deployed outside of the United States based solely on their HIV-positive status.
    [Show full text]
  • Efavirenz Is Predicted to Accumulate in Brain Tissue
    AAC Accepted Manuscript Posted Online 31 October 2016 Antimicrob. Agents Chemother. doi:10.1128/AAC.01841-16 Copyright © 2016, American Society for Microbiology. All Rights Reserved. 1 Efavirenz is predicted to accumulate in brain tissue: an in silico, in vitro and in vivo 2 investigation 3 4 Paul CURLEY1, Rajith K R RAJOLI1, Darren M MOSS1, Neill J LIPTROTT1+2, Scott Downloaded from 5 LETENDRE3, Andrew OWEN1+2 # and Marco SICCARDI1 6 7 1 Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, 8 Liverpool, UK 9 10 2 European Nanomedicine Characterisation Laboratory, Molecular and Clinical Pharmacology, http://aac.asm.org/ 11 Institute of Translational Medicine, University of Liverpool, Liverpool, UK 12 13 3 Departments of Medicine and Psychiatry, University of California San Diego, 220 Dickinson 14 Street, Suite A, San Diego, CA 92103, USA. 15 on November 7, 2016 by University of Liverpool Library 16 * Author for correspondence and reprints: Prof A Owen, Molecular and Clinical Pharmacology, 17 Institute of Translational Medicine, University of Liverpool, UK 18 Tel: +44 (0) 151 794 8211 19 Fax: + 44 (0) 151 794 5656 20 E-mail: [email protected] 21 Word Count: 3439 22 References: 34 23 Figures: 3 24 Tables: 2 25 Key words: efavirenz, PBPK, CNS and toxicity 26 Running (short) Title: Efavirenz Accumulation in Brain Tissue 27 28 Abbreviations: cisterna magna (CM), extra cellular fluid (ECF), intracellular space (ICS), left 29 ventricle (LV), nevirapine (NVP), permeability surface area product (log PS), physiologically based 30 pharmacokinetic (PBPK), rapid equilibrium dialysis (RED), sub arachnoid space (SAS), third and 31 fourth ventricles (TFV), van der Waals polar surface area (TPSA) and van der Waals surface area of 32 the basic atoms (vasbase).
    [Show full text]
  • Dosage of HIV Drug May Be Ineffective for Half of African-Americans 27 August 2014
    Dosage of HIV drug may be ineffective for half of African-Americans 27 August 2014 Many African-Americans may not be getting bloodstream, the Johns Hopkins team predicted. effective doses of the HIV drug maraviroc, a new And since 85 percent of participants in the study from Johns Hopkins suggests. The initial maraviroc dosing study were European-Americans, dosing studies, completed before the drug was who typically lack functional CYP3A5, the licensed in 2007, included mostly European- researchers surmised that the recommended dose Americans, who generally lack a protein that is key for maraviroc could be too low for anyone with two to removing maraviroc from the body. The current functional copies of the gene—including 45 percent study shows that people with maximum levels of of African-Americans. the protein—including nearly half of African- Americans—end up with less maraviroc in their To test this idea, the research team grouped 24 bodies compared to those who lack the protein healthy volunteers according to how many even when given the same dose. A simple genetic functional copies of the CYP3A5 gene they test for the gene that makes the CYP3A5 protein had—zero, one or two. They were each given a could be used to determine what doses would single dose of maraviroc in the recommended dose achieve effective levels in individuals, the of 300 milligrams, and each participant's blood was researchers say. taken at 10 time points over 32 hours. The results of the small study were published At almost all time points, the concentrations of online on Aug.
    [Show full text]